Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vedolizumab biosimilar - Alvotech

Next Previous
Drug Profile

Vedolizumab biosimilar - Alvotech

Alternative Names: AVT-16; AVT-80

Latest Information Update: 12 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alvotech
  • Class Anti-inflammatories; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Integrin alpha4beta7 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • Phase I Immunological disorders

Most Recent Events

  • 08 Jan 2026 Alvotech completes the Phase-I pharmacokinetics trials in Immunological disorders (In volunteers) in New Zealand, Australia (SC) (NCT06732804)
  • 19 Dec 2025 Alvotech Swiss AG terminates a phase-III clinical trials in Ulcerative colitis in Argentina, Bulgaria, Croatia, Georgia, Latvia, Poland, Romania, Serbia, Slovakia, Sri Lanka, Ukraine (IV, Infusion), following a sponsor decision unrelated to safety concerns, as the study was not required for product dossier submission (NCT06570772)
  • 27 Nov 2024 Alvotech completes a phase-I trial in Immunological disorders (In volunteers) in New Zealand (IV) (NCT06400719)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top